Introduction
Focal cerebral ischemia (stroke) is the third most common cause of death in the world (Hankey and Warlow, 1999; Hasegawa et al., 2006) . The ischemic neuronal damage is known to be related to mitochondria and endoplasmic reticulum dysfunction, activated oxygen species, increased expression of inflammatory cytokines and proteolytic enzymes (Heo et al., 1999; Zhao et al., 2004; Sarabi et al., 2008) , while the detailed molecular mechanisms are still unknown. In spite of the development of various therapeutic strategies including thrombolysis with tissue-type plasminogen activator (tPA) or free radical scavengers (Yepes et al., 2000) , it has been difficult to completely cure because of the intractable severe subsequent complications such as paralysis and cognitive dysfunction (Shinohara et al., 2009; Yagi et al., 2009 ). Thus, clarification of the detailed mechanisms responsible for the development of ischemic neuronal damage is urgently required. The aim of this study was to identify one of the key molecules involved in the ischemic neuronal damage.
Neuronal cell adhesion molecule (NCAM), a member of the immunoglobulin superfamily of cell recognition molecules, is expressed on the membranes of neurons and glial cells and promotes cell-cell interaction via homophilic and heterophilic binding (Povlsen et al., 2003; Maness and Schachner, 2007) . Importantly, NCAM is known to This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on April 18, 2017 jpet.aspetjournals.org Downloaded from JPET #178079 6 regulate these processes which influence cell adhesion, cell migration, and neurite outgrowth and be involved in development of the nervous system, in brain plasticity associated with learning and memory, and in neuronal regeneration (Maness and Schachner, 2007) . Furthermore, dysfunction of NCAM is reported to contribute to the development of neurological disorders such as schizophrenia, bipolar disorder and Alzheimer's disease (Vawter, 2000; Todaro et al., 2004; Maness and Schachner, 2007) .
NCAM is synthesized in three main membrane-bound isoforms, NCAM-120, NCAM-140, and NCAM-180 (Ronn et al., 1998) . Interestingly, among these isoforms, the proteolysis of NCAM-180 has been reported to relate to psychological disorders in humans (Poltorak et al., 1996; Vawter, 2000; Tanaka et al., 2007) . In addition, mice lacking NCAM-180 have deficits in learning, emotional memory, and sensory gating (Bukalo et al., 2004; Maness and Schachner, 2007) . Recently, matrix metalloproteinase (MMP), one of the proteolytic enzymes targeting NCAM (Hubschmann et al., 2005; Hinkle et al., 2006) , is reported to be activated by ischemic stress (Heo et al., 1999; Zhao et al., 2004) . Although some target molecules of MMP such as laminin or IL-1β are reported to be involved in neuronal death and/or development of neuronal injury (Gu et al., 2005; Kawasaki et al., 2008) , there are no reports indicating that the MMP-NCAM interaction is involved in the development of neuronal damage. Here, we focused on the This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on April 18, 2017 jpet.aspetjournals.org Downloaded from JPET #178079 7 involvement of MMP-mediated proteolysis of NCAM in the development of ischemic neuronal damage using middle cerebral artery occlusion (MCAO) model mice, a popular ischemic model in experimental stroke research that results in prominent ischemic damage as we described previously (Harada et al., 2009 ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Methods

Animals
The experiments were performed on male ddY mice (5-6 weeks old, SLC, Osaka, Japan) and MMP-9 KO (background of C57BL/6J) mice were kindly given by Nagoya University Research Institute of Environmental Medicine (Nagoya, Japan). As previously described (Mizoguchi et al., 2007) , MMP-9 homozygous KO mice (10-12-weeks old) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA), and crossed to C57BL/6J mice for eight generations before being made homozygous.
Wild type C57BL/6J mice were obtained from the Japan SLC (Osaka, Japan). The animals were housed at a temperature of 23-24°C with a 12-h light-dark cycle (lights on 8:00 a.m. to 8:00 p.m.). Food and water were available ad libitum. The present study was conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, adopted by the Japanese Pharmacological Society. In addition, all experiments were approved by the ethical committee for animals of Kobe Gakuin University (approval number: A 060601-10).
Drug treatments
GM6001
This article has not been copyedited and formatted. The final version may differ from this version. were administrated directly after preparation. Mice were injected with siRNA directed at NCAM (1 μg/mouse, i.c.v.) 72 h before MCAO to knock down NCAM protein levels.
I.c.v. administrations were performed as previously described (Haley and McCormick, 1957) . Briefly, a microsyringe with a 27-gauge stainless-steel needle was used for all experiments. Tubing covered all but the terminal 2.5 to 3.0 mm of the needle so as to This article has not been copyedited and formatted. The final version may differ from this version. 
Induction of ischemic/reperfusion injury
The experimental transient focal ischemia mouse model was generated by performing MCAO as described previously (Harada et al., 2009) . Briefly, mice were anesthetized with 2% isoflurane (Abbott Japan, Osaka, Japan) and maintained in an anesthetized state with 1% isoflurane. The rectal temperature was maintained at 37 ± 0.5°C with the use of a heating blanket (FH-100, Unique Medical, Osaka, Japan) that was feedback controlled by a rectal temperature probe (PTE-101, Unique Medical) and a small animal heat controller (ATC-101B, Unique Medical). The left common carotid artery (CCA) and external carotid artery (ECA) underwent a midline pretracheal incision.
The vagus nerves were separated carefully from the artery. CCA and ECA were ligated, and then the internal carotid artery (ICA) was isolated. Bifurcation of the CCA was made Kulzer, Hanau, Germany) was introduced through a small incision and was advanced 9 mm along the ICA beyond the bifurcation site, thus stopping the blood flow to the middle cerebral artery (MCA). After 2 h of ischemia, mice were re-anesthetized with isoflurane; then, the filament was withdrawn for blood reperfusion. The sham-operated mice were subjected to the procedure mentioned above without MCAO. The operative site was sutured and mice were allowed to awake from the anesthesia. Mice with brain hemorrhage were eliminated from analysis. The relative cerebral blood flow (rCBF) was measured by laser Doppler flowmetry (LDF; TBF-LN1, Unique Medical) to assess the adequacy of the vascular occlusion and reperfusion, as described previously (Harada et al., 2009 ).
Measurement of infarct volume
Mice were euthanized by cervical dislocation on day 1 and day 3 after MCAO.
The brains were cut into 2-mm thick coronal slices (-2, 0, +2 and +4 mm from the bregma) using a brain slicer. The brain slices were then incubated in normal saline containing 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma, MO, USA) for 10 min (intensity = intensity of left hemisphere -intensity of right hemisphere).
Measurement of brain edema
Brain edema was assessed by measuring the brain water content according to the wet-dry method as described previously (Ding-Zhou et al., 2003; Liu et al., 2008) . Briefly, after decapitation, the brain was quickly removed and dissected along the interhemispheric fissure into the ischemic and nonischemic cerebral hemispheres. Tissues were weighed with a scale to within 0.1 mg. Dry weight of the brain was determined after heating the tissue for 3 days at 100°C in a drying oven. Brain water content was then calculated as [(wet weight -dry weight)/wet weight] x 100.
Neurological examination
13
Neurological examination was performed using the neurological deficit score (NDS) comprising consciousness (0, normal; 1, restless; 2, lethargic; 3, stuporous; 4, seizures; and 5, death), walking (0, normal; 1, paw; 2, unbalanced walking; 3, circling; 4, unable to stand; and 5, no movement), and limb tone (0, normal; 1, spastic; and 2, flaccid), and pain reflex was scored after reperfusion as described previously (Harada et al. 2009 ). Pain reflex was assessed using the tail flick test (pain reflex = latency after MCAO -latency before MCAO). A cut-off time of 10 s was used to prevent any injury to the tail.
Western blot analysis
On indicated days after reperfusion, mice were decapitated and brains were removed. Ipsilateral cortex was dissected, and homogenized with homogenize buffer (20 mM Tris-HCl, pH 7.5, 120 mM NaCl, 4% Tween-20, 2 mM β -mercaptoethanol, 1 mM Na 3 VO 4 , 5 mM benzamidine, 20 mM NaF, 1 mM p-nitrophenyl phosphate, 5 mM imidazole, 50 mg/ml trypsin inhibitor, 50 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml pepstatin, 1 mM PMSF). After centrifugation at 15000 g, the supernatant was collected and immediately lysed in SDS-sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol), boiled and reduced with β-mercaptoethanol. To investigate protein expression 14 patterns in control and ischemic cortex, equal amounts (20 μg) of total protein extracts were prepared. After mixing with 2× sample buffer, each sample was separated by non-reducing gel in native condition for NCAM, MMP-2 and MMP-9 (120 V, 90 min).
Markers used were Precision Plus Protein Standards Kaleidoscope (Bio-Rad, CA, USA).
After separation, proteins were transferred to nitrocellulose membranes (15 V, 50 min).
All blots were blocked with 10% skim milk (blocking agent; GE Healthcare, Osaka, 
Gelatin Zymography
Similarly prepared protein samples (as in Western blot analysis) were incubated with 50% gelatin sepharose 4B (GE Healthcare, Osaka, Japan) for 4 h. After washing with wash buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 5 mM CaCl 2 , 0.05% BRIJ-35, 0.02% NaN 3 ), samples were eluted by elution buffer (50 mM Tris-HCl (pH 7.6),
Statistical analysis
Data are presented as means ± S.E.M. Comparisons of parameters at a given time point among multiple treatment groups, as well as within treatment group comparisons across more than two time points were conducted using a one-way analysis 
Results
Development of neuronal damage and protein levels or activity of MMP-2 and MMP-9 in the cerebral cortex after cerebral ischemic stress
As shown in Fig. 1A , the infarct area in the cortex, hippocampus and striatum was gradually enlarged on day 3 compared with on day 1 after MCAO ( Fig. 1A, B ). In addition, the increase of brain water content, indicating the development of edema, was significantly observed and gradually enlarged on day 1 and day 3 after MCAO ( Fig. 1C ).
In addition, NDS was significantly increased in the MCAO group than in the sham group on day 1 and day 3 (Fig. 1D ). In the western blot analysis, we detected a 72 kDa band for MMP-2 and 108 kDa band for MMP-9, and they were significantly increased on day 1 and day 3 after MCAO compared with the sham group (Fig. 1E, F) . The gelatin zymograms clearly demonstrated the increase of MMP-2 and MMP-9 activity on day 3 after MCAO. Semi-quantified data showed the significant differences, in a GM6001, a broad range MMP inhibitor, -reversible manner (Fig. 1G) .
Effect of NCAM siRNA on ischemic neuronal damage
To confirm the role of NCAM in MCAO-induced neuronal damage, we investigated whether NCAM knockdown increases the ischemic neuronal damage. Three
This article has not been copyedited and formatted. The final version may differ from this version. 18 days after NCAM siRNA administration, NCAM (180 kDa) protein levels were significantly decreased in the cortex in naïve mice ( Fig. 2A) . In addition, we confirmed the NCAM (180 kDa) protein levels were kept lower until 4 days after siRNA administration (data not shown). Thus, we performed MCAO on day 3 after NCAM siRNA administration.
The infarct volume was significantly increased on day 1 after MCAO in the NCAM siRNA-treated group compared with the control group (Fig. 2B, C) . NDS was also significantly increased in the NCAM siRNA-treated group than in the control group (Fig. 2D) . Since the development of infarction accomplishes maximum on day 3 after MCAO, it was hard to compare the difference between control and siRNA-treated group on day 3 after MCAO.
Protein levels of NCAM (180 kDa) and NCAM cleavage product (65 kDa) after cerebral ischemic stress
Since NCAM is one of the proteolysis targets of matrix metalloproteinase (MMP), the levels of NCAM (180 kDa) and NCAM cleavage product (65 kDa) after cerebral ischemic stress were determined. NCAM (180 kDa) protein levels were significantly decreased on day 1 after MCAO compared with the sham group, while it This article has not been copyedited and formatted. The final version may differ from this version. 19 returned to the sham levels on day 3 (Fig. 3A) . On the other hand, NCAM cleavage product levels (65 kDa) were significantly increased on day 1 and day 3 compared with the sham group (Fig. 3B) .
Effect of a non-selective MMP inhibitor, GM6001, on ischemic neuronal damage,
NCAM protein levels and NCAM cleavage product levels
We investigated whether MMP inhibitor suppresses the development of ischemic neuronal damage. As shown in Fig. 4A and B, the infarct volume observed on day 3 after MCAO was significantly decreased by treatment of GM6001 (Fig. 4) .
Furthermore, the ischemic stress-induced an increase of NDS was also significantly inhibited by GM6001 treatment (Fig. 4C ). In addition, the decrease in NCAM (180 kDa)
protein levels observed on day 1 were completely recovered to the control level by GM6001 (Fig. 4D ). In addition, the increment of NCAM cleavage product levels (65 kDa) observed on day 1 and day 3 was significantly suppressed by GM6001 (Fig. 4E) .
Effect of MMP isozyme-specific inhibitors on ischemic neuronal damage, NCAM protein levels and NCAM cleavage product levels
To determine which MMP plays critical role in MCAO, we used selective (Fig. 5A, B, and C). The decrease in NCAM (180 kDa) protein levels observed on day 1 was completely recovered to the control level by MMP-2 inhibitor III (Fig. 5D ). In addition, the increment of NCAM cleavage product levels (65 kDa) observed on day 1 and day 3
were significantly suppressed by this inhibitor (Fig. 5E ). Furthermore, treatment with the selective MMP-9 inhibitor I, showed the same results as the selective MMP-2 inhibitor III (Fig. 6 ).
Ischemic neuronal damage and NCAM protein levels, NCAM cleavage product levels after cerebral ischemic stress in MMP-9 KO mice
To confirm the role of MMP-9 in MCAO, we investigated whether MCAO shows ischemic neuronal damage using MMP-9 KO mice. Since C57BL/6 strain is known to be more susceptible to cerebral ischemia when compared to ddY mice (Yang et al., 1997) , here, we investigated only on day 1 after MCAO. The development of infarction was significantly reduced in the MMP-9 KO mice compared with WT mice on day 1 after MCAO ( Fig. 7A and B) . The NDS on day 1 was also significantly decreased in the MMP-9 KO mice compared with WT mice (Fig. 7C ). In addition, the decrease in , and NCAM-120 (120 kDa), which differ in their C-terminals (intracellular part) (Tacke and Goridis, 1991; Doherty et al., 2000) . NCAM is widely expressed in the nervous system where it plays a pivotal role in proliferation, migration, axonal outgrowth, fasciculation and synaptic plasticity (Ronn et al., 1998; Berezin et al., 2000; Povlsen et al., 2003; Maness and Schachner, 2007) . Furthermore, NCAM is found on glial and neuronal cells and participates in binding these cells together (Vawter, 2000) . It has been suggested that neuron-glia interactions are involved in the physiological function of neurons (Vawter, 2000; Chadi et al., 2009) . Aside from its role in cell-cell interactions, an important role for NCAM in regulation of intracellular signaling pathways has been revealed (Povlsen et al., 2003; Kiryushko et al., 2004) .
Recently, the protein levels of NCAM and its post-translational modified form polysialylated NCAM, have been reported to be highly susceptible to modulation by stress (Bisaz et al., 2009) . In regard to cerebral ischemic stress, the increase of polysialylated-NCAM was observed in the subventricular zone that is involved in the The ischemic stress induced not only the decrease of full length of NCAM (180 kDa), but also the increase of NCAM cleavage product (65 kDa), which is considered a proteolytic fragment of NCAM (Tanaka et al., 2007) by extracellular proteases. MMP is a family of zinc-dependent endopeptidases that can be released or activated in a neuronal activity dependent manner (Mizoguchi et al., 2007) and are attractive targets in the field of inflammatory and psychological diseases (Yong et al., 2001; Kawasaki et al., 2008; Mizoguchi et al., 2008) . They cleave all constituents of the ECM including collagens and laminins (Yong et al., 2001) . Recently, it has been well known that MMPs can also target a variety of non matrix proteins including varied soluble molecules, cell surface receptors and synaptic cell adhesion molecules (CAMs) including NCAM (Vawter, 2000; Conant et al., 2010) . The soluble extracellular domain of NCAM has been identified in normal brain, potentially arising from ectodomain shedding of the extracellular domain of transmembrane NCAM by MMPs (Hubschmann et al., 2005; Hinkle et al., 2006) .
There are at least 25 members of the MMP family and their activity is tightly regulated. Although MMPs are expressed in both glial and neuronal cell (Yong et al., 2001; Szklarczyk et al., 2002) , ischemic stress is known to induce MMP-2 and MMP-9, major isozymes in the MMP family, in glial cells such as reactive microglia and 25 astrocytes (Svedin et al., 2007) . Ischemic stress accompanies the progression of neuronal death via cleavage of precursors of inflammatory cytokines by MMP-2 and MMP-9 (Amantea et al., 2007; del Zoppo et al., 2007) .
In this study, MMP-2 and MMP-9 were significantly up-regulated on day 1 and day 3 after ischemic stress. The increased enzymatic activity of MMP-2 and MMP-9 was also detected on day 3 after ischemic stress, corresponding with the previous studies (Asahi et al., 2001; Lee et al., 2004; Koistinaho et al., 2005) . Since the increase of full length NCAM (180 kDa) was accompanied by the decrease of NCAM cleavage product (65 kDa) by an inhibition of MMP-2 and MMP-9, these changes seem to be due to the transmembrane proteolysis of NCAM via activation of these enzymes. Furthermore, the present results using MMP-9 null mice obviously support this hypothesis at least for the involvement of MMP-9.
As shown in the present study, the development of edema was significantly observed after ischemic stress. Since many reports have also demonstrated the proteolytic degradation by MMP of critical blood-brain barrier contributes the development of post-ischemic edema (Asahi et al., 2001; Lee et al., 2004; Svedin et al., 2007) , it is possible that NCAM is involved not only in the MMP-mediated development of ischemic neuronal damage but also in the MMP-mediated development of post-ischemic edema.
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and MMP-3 at higher concentrations, suggesting the possible involvement of MMPs other than MMP-2 and MMP-9, while it remains to be determined.
The increase of fragment of NCAM (65-70 kDa) and the other fragment of NCAM (105-115 kDa) has been reported in patients with schizophrenia or Alzheimer's disease (Vawter, 2000; Todaro et al., 2004; Tanaka et al., 2007) . Taken together, proteolysis of NCAM by MMP-dependent shedding (Hubschmann et al., 2005; Hinkle et al., 2006 ) may occurr in neurodegenerative disorders. Although we did not determine the alterations of NCAM fragment (105-115 kDa) under ischemic stress, the present findings indicate that the MMP-mediated NCAM proteolysis may be implicated in the exacerbation of ischemic neuronal damage. Furthermore, it is possible that the accumulation of NCAM cleavage product is related to a deteriorative or degenerative process in ischemic neuronal damage as described in the case of schizophrenia (Vawter, 2000) , however it remains to be determined.
In conclusion, we found that MMP-mediated decrease of full length NCAM GM6001, n = 12). **p < 0.01, ##p < 0.01, Steel-Dwass test. D, NCAM protein levels (180 kDa), (sham, n = 9; vehicle, n = 28; GM6001, n = 28). E, NCAM cleavage product levels (65 kDa) (day 1 sham, n = 9; day 1 vehicle, n = 28; day 1 GM6001, n = 28; day 3
sham, n = 20; day 3 vehicle, n = 28; day 3 GM6001, n = 28). The protein levels of NCAM were analyzed by western blotting. Each column indicates the mean ± S.E.M. *p< 0.05, **p < 0.01, #p < 0.05, ##p < 0.01, one-way ANOVA and Scheffe's test. MMP-2 III, n = 6). ##p < 0.01, unpaired Student's t-test. C, neurological examination was performed using the NDS. Results are expressed as mean ± S.E.M. (sham, n = 6; vehicle, n = 10; MMP-2 III, n = 6). **p < 0.01, ##p < 0.01, Steel-Dwass test. D, NCAM protein levels (180 kDa) (sham, n = 10; vehicle, n = 10; MMP-2 III, n = 4). E, NCAM cleavage product levels (65 kDa) (day 1 sham, n = 10; day 1 vehicle, n = 10; day 1 MMP-2 III, n = 14; day 3 sham, n = 10; day 3 vehicle, n = 10; day 3 MMP-2 III, n = 14). The protein levels of NCAM were analyzed by western blotting. Each column indicates the mean ± S.E.M. *p < 0.05, **p < 0.01, ##p < 0.01, one-way ANOVA and Scheffe's test. 43 NDS (sham, n = 4; vehicle, n = 4; MMP-9 I, n = 13). **p< 0.01, ##p< 0.01, Steel-Dwass test. D, NCAM protein levels (180 kDa) (sham, n = 10; vehicle, n = 11; MMP-9 I, n = 14).
E, NCAM cleavage product levels (65 kDa) (day 1 sham, n = 6; day 1 vehicle, n = 10; day 1 MMP-9 I, n = 10; day 3 sham, n = 10; day 3 vehicle, n = 14; day 3 MMP-9 I, n = 14).
The protein levels of NCAM were analyzed by western blotting. Each column indicates mean ± S.E.M. *p < 0.05; **p< 0.01, ##p< 0.01, one-way ANOVA and Scheffe's test.
Fig. 7
Ischemic neuronal damage and NCAM protein levels, NCAM cleavage product levels after cerebral ischemic stress in MMP-9 KO mice. A, representative photographs of infarct volume. B, quantitative analysis of the infarct volume (WT, n = 9; MMP-9 KO, n = 10). *p < 0.05, unpaired Student's t-test. C, neurological examination was performed using the NDS. (WT, n = 3; MMP-9 KO, n = 4). **p < 0.01, Wilcoxon-Mann-Whitney U test. D, NCAM protein levels (180 kDa) (sham WT, n = 10; WT, n = 10; MMP-9 KO, n = 14). E, NCAM cleavage product levels (65 kDa) (sham WT, n = 6; WT, n = 14; MMP-9 KO, n = 6). The protein levels of NCAM were analyzed by western blotting. Each column indicates mean ± S.E.M. *p < 0.05, ##p < 0.01, one-way ANOVA and Scheffe's test.
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